Article: Addition of ADVEXIN(R) to Chemotherapy Shows Promise in Treating Locally Advanced Breast Cancer.

- Combination Neoadjuvant Therapy Resulted in 100 Percent Tumor Response and Complete Surgical Removal -

Introgen Therapeutics, Inc. reported data from its Phase 2 trial evaluating ADVEXIN(R) combined with neoadjuvant chemotherapy in women with locally advanced breast cancer. Neoadjuvant treatments are administered prior to surgery and represent a novel and increasingly applied approach to make surgical tumor resections either more complete improving outcomes or less invasive facilitating breast conservation. Objective clinical responses with a greater than 50 percent reduction in tumor size were seen following the combined therapy in all of the patients. ...






Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!